World's Best Scientists 2026 revealed!
Osamu Yokosuka

Osamu Yokosuka

D-Index & Metrics

Medicine

D-Index
94
Citations
41934
World Ranking
10317
National Ranking
286

Overview

Osamu Yokosuka is affiliated with Chiba University in Japan and has a research focus grounded in the field of Medicine with a specialization in Hepatology. Their academic contributions encompass a broad scope of liver-related medical research, particularly regarding liver disease diagnosis, treatment, and transplantation.

Their work spans several key subfields including Hepatology, Epidemiology, Surgery, Pulmonary and Respiratory Medicine, and Oncology. Main topical areas covered by their research include:

  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Liver Diseases and Immunity
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatitis Viruses Studies and Epidemiology

Osamu Yokosuka has frequently published in several specialized venues, with a notable presence in:

  • Hepatology International
  • Hepatology Research
  • Journal of Hepatology
  • Liver International
  • Cancer Medicine

Their recent scholarly papers include:

  • Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study), 2020, Hepatology International
  • APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis, 2022, Hepatology International
  • APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19, 2020, Hepatology International
  • Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF, 2021, Hepatology International
  • Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials, 2020, Liver Cancer

The scientist has collaborated extensively with a group of frequent co-authors including Shiv Kumar Sarin, George Lau, Naoya Kato, Sombat Treeprasertsuk, and Rino Alvani Gani.

Best Publications

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

    Haruhiko Yoshida;Yasushi Shiratori;Mitsuhiko Moriyama;Yasuyuki Arakawa

  • Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)

    Shiv Kumar Sarin;Ashish Kumar;John A. Almeida;Yogesh Kumar Chawla

  • Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

    Yasushi Shiratori;Fumio Imazeki;Mitsuhiko Moriyama;Michitami Yano

  • Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties.

    Tetsuhiro Chiba;Kaoru Kita;Yun-Wen Zheng;Osamu Yokosuka

  • Mutations in the Precore Region of Hepatitis B Virus DNA in Patients with Fulminant and Severe Hepatitis

    Masao Omata;Toshiki Ehata;Osamu Yokosuka;Kazuhiko Hosoda

  • Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

    Hajime Sumi;Osamu Yokosuka;Naohiko Seki;Makoto Arai

  • Incidence of hepatocellular carcinoma in chronic Hepatitis B and C: A prospective study of 251 patients

    Susumu Takano;Osamu Yokosuka;Fumio Imazeki;Masami Tagawa

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • New Inuyama classification; new criteria for histological assessment of chronic hepatitis

    Fumihiro Ichida;Takao Tsuji;Masao Omata;Takafumi Ichida

  • Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

    Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto

  • Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival

    Yasushi Shiratori;Yoichi Ito;Osamu Yokosuka;Fumio Imazeki

  • Interferon therapy prolonged life expectancy among chronic hepatitis C patients.

    Haruhiko Yoshida;Yasuyuki Arakawa;Michio Sata;Shuhei Nishiguchi

  • Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

    Richard S. Finn;Philippe Merle;Alessandro Granito;Yi Hsiang Huang

  • Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

    Masatoshi Kudo;Kazuomi Ueshima;Osamu Yokosuka;Sadahisa Ogasawara

  • Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation.

    Tetsuhiro Chiba;Yun-Wen Zheng;Kaoru Kita;Osamu Yokosuka

  • Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).

    Shiv Kumar Sarin;Ashok Choudhury;George K. Lau;Ming-Hua Zheng

  • De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes.

    Hitoshi Maruyama;Hidehiro Okugawa;Masanori Takahashi;Osamu Yokosuka

  • Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

    Y Shiratori;N Kato;O Yokosuka;F Imazeki

  • Resolution of acute hepatitis C after therapy with natural beta interferon.

    M. Omata;O. Yokosuka;S. Takano;N. Kato

Frequent Co-Authors

Fumio Imazeki
Fumio Imazeki Chiba University
Hiromitsu Saisho
Hiromitsu Saisho Chiba University
Masao Omata
Masao Omata University of Tokyo
Masaru Miyazaki
Masaru Miyazaki International University of Health and Welfare
Kunio Okuda
Kunio Okuda Chiba University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Atsushi Iwama
Atsushi Iwama University of Tokyo
Shiv Kumar Sarin
Shiv Kumar Sarin Institute of Liver and Biliary Sciences
Michio Sata
Michio Sata Kurume University
George K. K. Lau
George K. K. Lau Humanity & Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always follow a traditional path. Many students consider what is the easiest nursing school to get into as a practical starting point, especially if they're seeking more accessible admission requirements and faster entry into the field.

For those who already have an RN license, most affordable accredited online rn to bsn programs offer a flexible way to advance your credentials and skills while balancing work or family commitments.

If you're from a non-nursing background but interested in healthcare, entry level msn programs online provide a unique opportunity to switch careers and quickly become a registered nurse with advanced qualifications.

Ambitious nurses may look toward leadership or teaching roles by pursuing a phd nursing education online, opening doors to research, academia, and advanced clinical practice. These pathways highlight the increasing accessibility and variety of online healthcare degrees for those pursuing a future in medicine.

Best Scientists Citing Osamu Yokosuka

Trending Scientists